Clinical Trial Update: Tislelizumab with Azacitidine in the Treatment of R/R AML [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update notes the phase 1/2 study of tislelizumab with azacitidine for refractory or relapsed acute myeloid leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Refractory AML, Relapsed Adult AML | Phase 1, Phase 2 | Status: WITHDRAWN